stockrowNatera, Inc.
NTRA Healthcare Diagnostics & Research
Natera, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 35.9% from fiscal 2024.
- Revenue
- +34.1%
- EPS
- +34.4%
- Free cash flow
- −85.8%
- Total debt
- −0.06%
Quarter to September 2026, against a year earlier
Follow NTRA
Alert me
Natera, Inc. (NTRA) Return on invested capital
Natera, Inc.'s return on invested capital over the twelve months to 30 September 2026 was −8.35%, up 18.7 percentage points from fiscal 2025 (−27.0%). Over the past ten years it has ranged from −10,224.9% (fiscal 2020) to 0.00% (fiscal 2019); the current reading is higher than 73% of that period. That is below the Diagnostics & Research industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −27.0% | 18.15 |
| FY2024 | −45.2% | 66.52 |
| FY2023 | −111.7% | 87.97 |
| FY2022 | −199.7% | 222.93 |
| FY2021 | −422.6% | 9,802.30 |
| FY2020 | −10,224.9% | (10,224.90) |
| FY2019 | 0.00% | 0.00 |
| FY2018 | 0.00% | 285.12 |
| FY2017 | −285.1% | 425.14 |
| FY2016 | −710.3% | (710.26) |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| IDXX IDEXX Laboratories, Inc. compare | 46.0% |
| MTD Mettler-Toledo International, Inc. compare | 35.4% |
| ILMN Illumina, Inc. compare | 16.7% |
| A Agilent Technologies, Inc. compare | 11.1% |
| DGX Quest Diagnostics Incorporated compare | 8.48% |
| IQV IQVIA Holdings Inc. compare | 6.79% |
| LH Labcorp Holdings Inc. compare | 6.76% |
| WAT Waters Corporation compare | 1.13% |
| NTRA Natera, Inc. | −8.35% |
| Diagnostics & Research industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on NTRA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement